From JPMA New Year's Message for 2022
At the beginning of the year 2022, I would like to extend my best wishes for the New Year.
As the world faces the threat of a pandemic of a new type of coronavirus, more than 5 million people have died so far. In Japan, the number of infected people has been suppressed and there are signs that the situation is under control, thanks to the progress of vaccination and thorough infection control measures taken by the Japanese people. However, the emergence of the Omicron strain, and other factors such as the global infection situation still leave us in an unpredictable situation. We would like to express our deepest sympathies to those who have been infected and to the families of those who lost their lives.
The pharmaceutical industry is working diligently to develop domestically produced vaccines and oral therapies to put an end to the battle against the new coronavirus, and we are steadily preparing for the next pandemic through close cooperation between industry, academia, and government.
The year 2021 was a major milestone for the pharmaceutical industry. The recent pandemic has led to the recognition of pharmaceuticals as an important strategic asset for security, and the "Growth Strategy Action Plan" approved by the Cabinet in June positioned life sciences as an important strategic field along with digital and green. In September, the Ministry of Health, Labour and Welfare (MHLW) issued the "Pharmaceutical Industry Vision 2021" for the first time in eight years, which develops pharmaceutical industry policies targeting innovative drug discovery, generic drugs, and drug distribution, while adding an economic security perspective. The pharmaceutical industry welcomes the development of the vision and will do its utmost to fulfill the expectations of the vision.
Japan Pharmaceutical Manufacturers Association, Inc.
Yasushi Okada, Chairman
In order for Japan to continue to produce innovative new drugs, it is necessary to build a drug discovery ecosystem in which industry, academia, and government collaborate to link the promising seeds of venture companies and academia to practical applications. To this end, it is necessary to create a bio-community, similar to Boston in the U.S., where people with entrepreneurial spirit gather, ventures start up with cutting-edge research, and various research institutions organically collaborate; to develop a health and medical big data infrastructure; and to establish a drug pricing system that appropriately evaluates innovation. In particular, it is essential that an appropriate drug price level based on the value of innovation be maintained during the patent period, and that the cycle of reinvesting the revenue generated from such innovation in the creation of further innovation be continued. In this regard, the "system to maintain drug prices during the patent term" is the lifeline that supports the pharmaceutical industry.
The Pharmaceutical Manufacturers Association of Japan and its member companies are committed to creating innovative new drugs that satisfy unmet medical needs and support the extension of healthy life expectancy of the Japanese people, as well as being a key industry that drives the growth of the Japanese economy. I would like to conclude my New Year's greetings by asking for your understanding and support.
(From the New Year's New Year's letter of the Honmachi Press Association)
Japan Pharmaceutical Manufacturers Association (JPMA)
Japan Pharmaceutical Manufacturers Association (JPMA)
The Pharmaceutical Manufacturers Association of Japan (PMAJ), founded in 1968, is an association of R&D-oriented pharmaceutical companies that aim to contribute to the improvement of health and welfare of people around the world through research and development of ethical drugs for use in hospitals, clinics, and other medical institutions.
The organization is dedicated to promoting a deeper understanding of pharmaceuticals and providing policy recommendations for the sound development of the pharmaceutical industry, with the aim of realizing patient-participatory medicine.
As a member organization of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the Pharmaceutical Manufacturers Association of Japan (PAPJ) is engaged in global activities in cooperation with other organizations to address issues related to medicine and pharmaceuticals around the world.
Aiming to contribute to society through the development of new drugs Japan Pharmaceutical Manufacturers Association